Table 1.
Characteristics of ovarian cancer case-control populations analyzed in this study*
| Study | Country | Control patients | Case patients | ||||
|---|---|---|---|---|---|---|---|
| No. | Mean age, y (range) | No. | Mean age, y (range) | High-grade serous | Stage 3/4 | ||
| No. (%) | No. (%) | ||||||
| AOC | Australia | 648 | 57 (20–80) | 630 | 61 (23–80) | 573 (90.9) | 545 (86.5) |
| GRR | USA | 0 | NA | 126 | 48 (21–80) | 70 (55.6) | NA |
| HJO/HMO | Germany/Belarus | 526 | 36 (18–68) | 335 | 58 (18–88) | 173 (51.6) | 156 (46.6) |
| LAX | USA | 210 | 61 (34–90) | 199 | 62 (32–88) | 199 (100) | 183 (92.0) |
| MAY | USA | 660 | 63 (26–93) | 650 | 64 (23–91) | 642 (98.8) | 581 (89.4) |
| RMH | UK | 0 | NA | 64 | 53 (27–73) | 64 (100) | NA |
| SEA | UK | 843 | 53 (28–66) | 712 | 57 (24–74) | 356 (50.0) | 393 (55.2) |
| STA | USA | 171 | 48 (20–66) | 163 | 53 (23–64) | 129 (79.1) | 121 (74.2) |
| UKO | UK | 373 | 65 (52–78) | 357 | 61 (25–90) | 329 (92.2) | 244 (66.4) |
| Total | 3,431 | 55 (18–93) | 3,236 | 58 (18–91) | 2535 (78.3) | 2223 (68.7) | |
* All studies are case-control studies except for: GRR, familial ovarian cancer registry study, and RMH, case-only hospital study; high-grade serous ovarian cancers includes 304 cases that were serous subtype but of unknown grade. AOC = Australian Ovarian Cancer Study; GRR = Gilda Radner Familial Ovarian Cancer Registry; HJO = Hannover-Jena Ovarian Cancer Study; HMO = Hannover-Minsk Ovarian Cancer Study; LAX = Women’s Cancer Program at the Samuel Oschin Comprehensive Cancer Institute; MAY = Mayo Clinic Ovarian Cancer Case-Control Study; RMH = Royal Marsden Hospital Ovarian Cancer Study; SEA = Study of Epidemiology and Risk Factors in Cancer Heredity; STA = Family Registry for Ovarian Cancer and Genetic Epidemiology of Ovarian Cancer; UKO = United Kingdom Ovarian Cancer Population Study.